You are here: Industry Insights > Paxlovid

News List

New COVID 19 Treatment Options Amid Falling Reported New Cases SHEM OIRERE
August 16, 2023
The proportion of countries reporting COVID 19 cases has been declining since mid-2022 even as testing for and reporting of new cases reduce hence impacting uptake of drugs and associated active pharmaceutical ingredients.
Sinopharm announces that Paxlovid from Pfizer is Available in China PharmaSources
March 01, 2023
China National Pharmaceutical Group (Sinopharm) announced that Paxlovid from Pfizer is allowed to introduce in China. Here is the news from Pharma Sources.
China approves use of Pfizer’s COVID drug Paxlovid ExpressPharma
February 15, 2022
It is not immediately clear if China is already in talks with Pfizer to procure the pill.
Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment FirstWordPharma
February 14, 2022
Singapore has received its first batch of Pfizer's oral COVID-19 treatment Paxlovid, after authorities last week said they had approved the tablet for COVID-19 in adults at risk for severe disease, reported CNA.
Pfizer reports 92% operational growth in full-year 2021 revenues Pharmaceutical-Technology
February 10, 2022
The company provided full year 2022 guidance for revenues in the range of $98bn to $102bn.
Pfizer receives CHMP positive opinion for novel COVID-19 oral treatment WorldPharmaNews
February 07, 2022
Pfizer Inc. (NYSE: PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization...
EU drug regulator OKs Pfizer COVID pill for high-risk patients ExpressPharma
January 29, 2022
The endorsement by EMA for a conditional approval, if followed as usual by the European Commission, allows EU member states to deploy the drug after the regulator gave guidance for its emergency use late last year.
Pfizer obtains positive EMA CHMP opinion for oral Covid-19 treatment Pharmaceutical-Technology
January 29, 2022
The recommendation is based on scientific data including results from the Phase II/III EPIC-HR clinical trial of Paxlovid.
Australian TGA grants approval to two oral medicines for Covid-19 Pharmaceutical-Technology
January 21, 2022
The Australian Therapeutic Goods Administration (TGA) has provisionally approved the use of two oral Covid-19 treatments, Merck Sharp & Dohme’s Lagevrio (molnupiravir) and Pfizer’s Paxlovid (nirmatrelvir and ritonavir).
Ascletis announces signing of Ritonavir tablet purchase agreement with Phokam Pharmaceutical ExpressPharma
January 20, 2022
Ascletis Pharma Inc recently announced the signing of the Ritonavir tablet purchase agreement between Phokam Pharmaceutical Import-Export (as buyer) of Laos and Ascletis Pharmaceuticals (as seller), a wholly-owned subsidiary of Ascletis Pharma Inc.

Previous page 1 2 3 4 Next page